M&A: Mosaic ImmunoEngineering Inc.

Form Type: 8-K

Filing Date: 2025-01-02

Corporate Action: Acquisition

Type: Update

Accession Number: 000168316825000009

Comments: Mosaic ImmunoEngineering, Inc. has extended the expiration date of its binding term sheet with Oncotelic Therapeutics, Inc. to June 30, 2025. The binding term sheet was initially entered into on April 26, 2024, and involves the acquisition of certain rights to technologies from Oncotelic, including their clinical stage necroptosis cancer therapies and proprietary AI technologies for identifying immunotherapy combinations. In exchange for these rights, Mosaic plans to issue Oncotelic shares valued at $15 million upon the execution of a definitive agreement, with potential additional shares worth up to $15 million contingent on milestones. The parties are negotiating the definitive agreement, but no guarantees for a transaction have been established.

Document Link: View Document